Poly(ethylene-co-methyl acrylate)/poly(caprolactone) triol blends for drug delivery systems: characterization and drug release

Κanis, Luiz Alberto; Soldi, Valdir

doi:10.1590/s0100-40422012000200012

Cited by 5 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That diltiazem hydrochloride release of polyethylene-co-methyl acrylate matrices containing PCL-T increase when the study was performed at a temperature of 37 o C. 26 This was explained by the ability of PCL-T fusion at this temperature, a fact that favors the simultaneous diffusion of the drug and the PCL-T matrix. If the release of sodium diclofenac from the matrix was solely dependent on diffusion through the polymer matrix, the release would probably follow a Fickian behavior, which would cause a reduction in the amount of drug released due to time constraints.…”

Section: Drug Releasementioning

confidence: 99%

Dispositivo implantável de EUDRAGIR/PCL-T/ Diclofenaco de sódio: caracterização mecânica, liberação do fármaco e atividade anti-inflamatóriain vivo

Cunha¹,

Moterle²,

Cunha³

et al. 2016

Medicina (Ribeirão Preto)

Self Cite

View full text Add to dashboard Cite

Modelo do estudo: experimental. Objetivo do estudo: produzir, descrever e avaliar a atividade antiinflamatória de um sistema polimérico implantável contendo diclofenaco de sódio na inflamação aguda induzida por carragenina em um modelo de artrite emjoelho de ratos. Metodologia: Um dispositivo implantável de Eudragit RS 100 e PCL-T (EUDPCL-T) contendo 3.0 mg de diclofenaco de sódio foi produzido. Os dispositivos foram implantados na região peri-articular posterior dos joelhos de ratos induzidos a artrite. Resultados: Após 6 horas e no dia 7 após a indução de artrite, o edema do joelho foi avaliado, e os mediadores inflamatórios, mieloperoxidase (MPO) e óxido nítrico foram analisados. Os resultados foram comparados com a administração oral de 30 mg / kg de diclofenaco de sódio. Conclusões: O dispositivo implantável foi capaz de produzir os mesmos resultados anti-inflamatórios na artrite induzida por carragenina quando comparadoscom o tratamento por via oral, entretanto com doses mais baixas

show abstract

Section: Drug Releasementioning

confidence: 99%

Dispositivo implantável de EUDRAGIR/PCL-T/ Diclofenaco de sódio: caracterização mecânica, liberação do fármaco e atividade anti-inflamatóriain vivo

Cunha¹,

Moterle²,

Cunha³

et al. 2016

Medicina (Ribeirão Preto)

Self Cite

View full text Add to dashboard Cite

show abstract

“…PCL Triol is a biodegradable, semi-crystalline, aliphatic polyester, with low molecular weight and melting point which has been investigated to a great extent as a biomaterial as well as in drug delivery applications [32][33][34]. One reason for this is the degradation products of PCL being naturally occurring metabolites in the human body with sutures composed of PCL being approved by the US Food and Drug Administration (FDA) [35].…”

Section: Stereolithographic Printing Processmentioning

confidence: 99%

“…One reason for this is the degradation products of PCL being naturally occurring metabolites in the human body with sutures composed of PCL being approved by the US Food and Drug Administration (FDA) [35]. Further to this, low molecular weight PCL Triols have been investigated for their potential to act as plasticizers [33,36,37] with Kanis et al [34] indicating that it is the three hydroxyl groups present which allow it to act as a plasticizer. Furthermore, PCL Triols due to their nature do not possess photopolymerizable terminal groups and therefore cannot crosslink on their own which is why PCL derivatives have been developed [38][39][40].…”

Section: Stereolithographic Printing Processmentioning

confidence: 99%

“…Furthermore, the addition of low molecular weight molecules added to polymer matrices have been reported to have the ability to modulate drug release due to a reduction in the polymer-polymer interactions as a result of the plasticization effect [32,36,37]. Kanis et al [34] conducted a study evaluating the effect of PCL Triol content imparted on drug release from a poly(ethylene-co-methyl acrylate) matrix and found that by increasing the amount of PCL Triol resulted in a lower amount of drug being released from the matrix. Therefore, it could be possible to control and manipulate the rate at which drug is released from the dosage form by adjusting the ratio of PCL Triol to PEGDA in the formulation, which would be advantageous if immediate release was a requirement of the dosage form.…”

Section: Dissolution Analysismentioning

confidence: 99%

See 1 more Smart Citation

Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography

et al. 2019

View full text Add to dashboard Cite

The introduction of three-dimensional printing (3DP) has created exciting possibilities for the fabrication of dosage forms, paving the way for personalized medicine. In this study, oral dosage forms of two drug concentrations, namely 2.50% and 5.00%, were fabricated via stereolithography (SLA) using a novel photopolymerizable resin formulation based on a monomer mixture that, to date, has not been reported in the literature, with paracetamol and aspirin selected as model drugs. In order to produce the dosage forms, the ratio of poly(ethylene glycol) diacrylate (PEGDA) to poly(caprolactone) triol was varied with diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (Irgacure TPO) utilized as the photoinitiator. The fabrication of 28 dosages in one print process was possible and the printed dosage forms were characterized for their drug release properties. It was established that both drugs displayed a sustained release over a 24-h period. The physical properties were also investigated, illustrating that SLA affords accurate printing of dosages with some statistically significant differences observed from the targeted dimensional range, indicating an area for future process improvement. The work presented in this paper demonstrates that SLA has the ability to produce small, individualized batches which may be tailored to meet patients’ specific needs or provide for the localized production of pharmaceutical dosage forms.

show abstract

“…PCL-T ( Figure 1) has three hydroxyl groups, which are able to plasticize some natural polymers, such as soy protein and cellulose acetate, and modify the drug-release properties of poly(ethylene-co-methyl acrylate) at body temperature. [17][18][19] PCL-T/cellulose acetate butyrate blends could become a novel polymeric material for implantable drug-delivery systems. Therefore, the purpose of this study was to evaluate the miscibility, mechanical, and water-swelling properties of semi crystalline CAB and PCL-T as well as the inflammatory response they induce in vivo.…”

Section: Introductionmentioning

confidence: 99%

Cellulose acetate butyrate/poly(caprolactonetriol) blends: Miscibility, mechanical properties, and in vivo inflammatory response

et al. 2014

View full text Add to dashboard Cite

This study reports the results of the characterization of cellulose acetate butyrate and polycaprolactone-triol blends in terms of miscibility, swelling capacity, mechanical properties, and inflammatory response in vivo. The cellulose acetate butyrate film was opaque and rigid, with glass transition (T g ) at 134℃ and melting temperature of 156℃. The cellulose acetate butyrate/polycaprolactone-triol films were transparent up to a polycaprolactone-triol content of 60%. T g of the cellulose acetate butyrate films decreased monotonically as polycaprolactone-triol was added to the blend, thus indicating miscibility. FTIR spectroscopy revealed a decrease in intramolecular hydrogen bonding in polycaprolactone-triol, whereas no hydrogen bonding was observed between cellulose acetate butyrate and -OH from polycaprolactone-triol. The increase in polycaprolactone-triol content in the blend decreased the water uptake. An increase in polycaprolactone-triol content decreased the modulus of elasticity and increased the elongation at break. A cellulose acetate butyrate/polycaprolactone-triol 70/30 blend implanted in rats showed only an acute inflammatory response 7 days after surgery. No change in inflammation mediators was observed.

show abstract

Poly(ethylene-co-methyl acrylate)/poly(caprolactone) triol blends for drug delivery systems: characterization and drug release

Cited by 5 publications

References 20 publications

Dispositivo implantável de EUDRAGIR/PCL-T/ Diclofenaco de sódio: caracterização mecânica, liberação do fármaco e atividade anti-inflamatóriain vivo

Dispositivo implantável de EUDRAGIR/PCL-T/ Diclofenaco de sódio: caracterização mecânica, liberação do fármaco e atividade anti-inflamatóriain vivo

Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography

Cellulose acetate butyrate/poly(caprolactonetriol) blends: Miscibility, mechanical properties, and in vivo inflammatory response

Contact Info

Product

Resources

About